Upon confirming the overactivation of the JAK1/2-STAT3 signaling pathway within the ATC cell lines and clinical samples, we proceeded to evaluate the effects of Ruxo using various thyroid cell lines, NTHY, TPC-1, BCPAP, IHH4, 8505 C, KHM-5M, C643, CAL-62 and BHT101 in vitro. This evidence concerns the gene JAK1 and thyroid gland disorder.